Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 20 of 25
  1. alpha 1H, Placebo product for Alpha1H

    Lacuna Pharma Pty Ltd

    Non-muscle invasive bladder cancer awaiting transurethral surgery

    phase 2 small molecule active

    1 trial
  2. placebo

    Nektar Therapeutics UK Limited

    Opioid Induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial
  3. placebo

    The First People's Hospital of Lianyungang

    COVID-19 Thalidomide

    phase 2 small molecule active

    1 trial
  4. placebo

    Universal Integrated

    Postprandial Distress Syndrome

    phase 2 small molecule active

    1 trial
  5. placebo mouthwash

    BRIGHT MINDS BIOSCIENCES INC.

    Dentinal Hypersensitivity

    phase 2 other completed

    1 trial
  6. placebo of BAY 3427080, BAY 3427080

    Bayer AG

    Sleep disturbances associated with menopause

    phase 2 small molecule active

    1 trial
  7. telaprevir or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  8. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial
  9. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial
  10. A clinical study of MK-5661 and placebo in healthy people (MK-5661-006)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial
  11. A clinical study of MK-6916 and placebo in healthy people (MK-6916-003)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial
  12. A randomized double-blind placebo-controlled... for Circulatory shock

    Lacuna Pharma Pty Ltd

    Circulatory shock

    phase 1 other active

    1 trial
  13. AK120 or placebo- Part 1- Cohort 1

    Akeso

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial
  14. Amoxicillin + MMX placebo

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial
  15. Ciprofloxacin XR + MMX Placebo

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial
  16. ETC-1002 or placebo

    Esperion Therapeutics

    Mild Dyslipidemia

    phase 1 small molecule completed

    1 trial
  17. Epetraborole and matching placebo

    AN2 Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  18. FTX-6058/placebo oral capsule(s)

    Fulcrum Therapeutics

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial
  19. HY-2003 (10 mg/ml), BELKYRA and placebo

    The First People's Hospital of Lianyungang

    Moderate or Severe Submental Fullness

    phase 1 small molecule active

    1 trial
  20. Ixazomib (NINLARO®) capsules / Matching placebo capsules

    Takeda

    Relapsing Remitting Multiple Sclerosis

    phase 1 small molecule active

    1 trial
  21. KT-474/Placebo

    Kymera Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial
  22. MT203 80 mg or matching Placebo

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  23. Metronidazole + MMX Mesalazine/mesalamine placebo

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial
  24. PF-07868489 Placebo, PF-07868489

    Pfizer Australia Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.